You identify yourself and that you are their constituent. You identify the healthcare issue based on external evidence to support the issue (use a scholarly reference). You identify your stance based

on the external evidence. You ask the Representative or Senator to support your view of the House or Senate bill; you want them to vote your way. At the end of the letter, include gratitude for their time and attention to the issue. At the bottom of the letter, include the reference used to support your identified issue. Make sure to use scholarly evidence need turinitin report Need to this work in 400 words/n You will write a letter to one of your legislators (for which you are a constituent) based on an Ohio House or Senate current bill (in this General Assembly) that you find has healthcare relevancy and is interesting to you. In the letter: You identify yourself and that you are their constituent. You identify the healthcare issue based on external evidence to support the issue (use a scholarly reference). • You identify your stance based on the external evidence. You ask the Representative or Senator to support your view of the House or Senate bill; you want them to vote your way. At the end of the letter, include gratitude for their time and attention to the issue. At the bottom of the letter, include the reference used to support your identified issue. ● • • • Please review the rubric for required letter content and points. No handwritten letters will be accepted. Below is an example of a well-done letter; please know this is only an example; do not copy in any part of the letter (If so, this will show on the Turnitin report). Dear Representative Stewart, My name is First and Last Name and I am a student, and I am currently a Junior in the BSN program. I live in District 12. I am writing to you in regards to House Bill (H.B. 24) of the 135th General Assembly and am requesting your support. House Bill 24 was introduced to require the Medicaid program and health benefit plans to ensure coverage of biomarker testing. HB 24 would enact sections 3902.63 and 5164.13 of the Revised Code, and is sponsored by Representative Andrea White of District 36. HB 24 has twelve co-sponsors. This bill was introduced to the House of Representatives on February 15, 2023 and was referred to the House Judicial Committee for review on February 16, 2023. H.B. 24 would ensure healthcare benefits would include the cost of biomarker testing. Although more research can support the existing evidence, there is data that notes such biomarker testing is low in cost. Yet without such testing, access to testing provides great benefits that outweigh the nominal costs (Hess et al., 2022). This testing includes diagnosis, treatment, and monitoring of a disease or condition (H.B. 24, 135th General Assembly, 2023, p. 1-2). The coverage would include a plan that was issued, renewed, or modified in the state of Ohio. The Biomarker testing would be supported by medical and scientific evidence to help diagnose or treat a disease (H.B. 24, 135th General Assembly, 2023, p. 2). The National Institute of Health (NIH) stated biomarkers may reflect the presence and/or severity of a disease, and could show how the body may respond to treatment of the disease or condition (Lyons, 2012). Biomarkers may be viewed as direct or indirect markers of the extent of disease, but regardless, they typically lie outside the causal pathway. They are used to monitor the burden of clinical or subclinical disease (Lyons & Basu, 2012). Biomarker testing could show the healthcare provider if a patient is suffering from a disease or condition that may otherwise be missed during an appointment. Every test completed in healthcare has an associated cost, and if the insurance companies are required to cover the biomarker screening, it would decrease the cost to the family, and could potentially save a life. H.B. 24 states biomarker testing would be supported by medical and scientific evidence by: • Labeled indications for a United States food and drug administration approved or cleared test (H.B. 24, 2023, p. 2) • Indicated tests for a drug approved by the United States Food and Drug Administration (H.B. 24, 2023, p.2) • Nationally recognized clinical practice guidelines (H.B. 24, 2023, p.2). I am asking for your full support of HB 24 so that more Americans are able to afford the biomarker testing that could alter their life. Biomarker testing has the potential to save a life, affect the care received, and alter the family life of the patient. I am in full support of H.B. 24, as I feel that all insurance companies should cover the cost of this test. There are individuals who put off receiving necessary testing due to the high cost. Americans pay for health insurance monthly and there should be more testing included in the cost that already seems high to some individuals. I would like to thank you for taking the time to consider my request, and I am available to answer any questions you may have. Thank you, Your constituent, (sign your name; you may use an electronic signature here) First and Last Name 1234 Smart Student Lane Columbus, Ohio 43222 References Hess, L.M., Michael, D., Krein, P. M., Marquart, T., & Sireci, A. N. Costs of biomarker testing among patients with metastatic lung or thyroid cancer in the USA: A real-world commercial claims database study. Journal of Medical Economics, 26(1), 43-50. https://doi.org/10.1080/13696998.2022.21544 H.B. 24, 135th General Assembly. (Ohio, 2023).https://legislature.ohio.grove/legislation/135/hb24 Lyons, T. J., & Basu, A. (2012). Biomarkers in diabetes: Hemoglobin A1c, vascular and tissue markers. Translational Research: The Journal of Laboratory and Clinical Medicine, 159(4), 303–312. https://doi.org/10.1016/j.trsl.2012.01.009